Nov 4, 2020

Creoptix on a Quest to Change Drug Discovery

at SwissCanto Invest, Investor Event 2020

Linked In Pic Swiss Canto Nov2020

Continue following us as we help shorten the time-to-market of drugs

Our CEO, Line Stigen Raquet, was amongst the six executives from SwissCanto Invest portfolio companies presenting at their Investor Event 2020 this week.

Bottom line: Creoptix is very well positioned for growth in the Drug Discovery market with its WAVEsystem and a disruptive and innovative cutting-edge technology portfolio aimed at helping deliver new drugs, vaccines and therapies faster to the market.